Industry news
The haemophilia business of Biogen is transferred to Bioverativ Inc.
The haemophilia business of Biogen transferred to newly formed Bioverativ Inc.on 1 February 2017 and Bioverativ Inc. now markets Alprolix and Eloctate/Elocta in its defined territories, and is developing a pipeline of pre-clinical drugs for haemophilia, beta-thalassaemia and sickle cell disease.